Drug Profile
Research programme: intranasal cancer vaccine - BlueWillow Biologics
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator NanoBio Corporation; University of Michigan
- Developer BlueWillow Biologics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in USA (Intranasal)
- 30 May 2018 BlueWillow Biologics in-licenses 'cancer vaccine compositions and their method of use' from the University of Michigan prior to May 2018
- 30 May 2018 University of Michigan has patent protection for 'Cancer vaccine compositions and methods of using the same' in USA